Editorial Article: Virtual Biopharmaceuticals Summit 2022: Full meeting agenda for November 22
Scientists from AstraZeneca, Bayer, Eli Lilly, Janssen, Roche, and other leading biopharma companies present on the latest topics biotherapeutic research and development
The full exciting schedule has been announced for the SelectScience® Virtual Biopharmaceuticals Summit, taking place on November 22, in partnership with BioPhorum. Featuring presentations from AstraZeneca, Bayer, Eli Lilly, Janssen: Pharmaceutical Companies of Johnson & Johnson, and Roche scientists among others, this free-to-attend online event offers an interactive forum for scientists and manufacturers to connect, showcase the latest research, and share cutting-edge technology solutions for biopharmaceuticals research and development.
You can look forward to topics including:
- Novel approaches for therapeutic monoclonal antibody discovery
- Streamlined methods for binding kinetics
- The latest trends in cell and gene therapy
- Mass spectrometry techniques for oligonucleotides and larger nucleic acids
- The latest in adeno-associated viruses (AAVs) critical quality attribute (CQA) analysis
- Pharmaceutical compliance, and much more
The Summit will host talks by world-leading scientists, live Q&As, video interviews, interactive resource booths, and unique networking opportunities. Attendees will also be able to view academic and industry posters submitted by our global scientific community, leave comments, ask questions, and prompt collaboration through 1-on-1 chat facilities.
Register now to catch the talks that are most relevant to your work, and read on to learn more about:
Keynote speakers
- Paul Anderson, Director, Biologics Discovery Automation, Eli Lilly
- Dr. Andrew Mahan, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson
Agenda
Tuesday, November 22
The Summit sessions take place in two concurrent tracks. Track 1 talks cover a range of topics in both Cell Line Development and Gene Therapy, while Track 2 is focused on Bioanalysis techniques. Times in bold are shown as Greenwich Mean Time (GMT).
| 11:30 12:30 (CET) 06:30 (EST) 03:30 (PST) |
|
Opening address & Poster session |
| 12:00 13:00 (CET) 07:00 (EST) 04:00 (PST) |
|
Analysis of critical quality attributes of adeno-associated viruses (AAVs) Dr. Farihah Haque, Product Specialist for GPC/SEC, Tosoh Bioscience |
|
Pharma compliance David Grant, Global Product Manager, ELGA LabWater |
| 12:45 13:45 (CET) 07:45 (EST) 04:45 (PST) |
|
Applying a matrix approach for potency assay development for in vivo and ex vivo gene therapies Dominic Hildebrand, Head of Laboratory / QC & Analytical Development, BayerShihua Lin, Pharmaceutical R&D Scientist, AstraZeneca Sarah Currie, Account Manager, BioPhorum |
|
Biolayer interferometry as an alternative to surface plasmon resonance in a biopharma regulated environment Dr. Arnaud Delobel, R&D and Innovation Director, Strategy & Innovation, Quality Assistance S.A. |
| 13:15 14:15 (CET) 08:15 (EST) 05:15 (PST) |
|
Semi-targeted spent media LC-MS assay: Assuring product quality during cell line development for biologics Keynote: Dr. Andrew Mahan, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson |
| 14:00 15:00 (CET) 09:00 (EST) 06:00 (PST) |
|
Go beyond titer and select top producers with favorable quality attributes within 5 days of cloning Dr. Aurora Fabry-Wood, Product Manager, Cell Line Development, Berkeley Lights |
| 15:00 16:00 (CET) 10:00 (EST) 07:00 (PST) |
|
Single cell antibody discovery using ‘Islands of automation' Keynote: Paul Anderson, Director - Biologics Discovery Automation at Eli Lilly |
|
Recent advances in oligo purity and sequence determination by LCMS: Maximizing throughput, confidence, and coverage Dr. Peter Rye, Application Engineer, Agilent Technologies |
| 15:45 16:45 (CET) 10:45 (EST) 07:45 (PST) |
|
Virtual coffee break - Connect with fellow attendees |
| 16:05 17:05 (CET) 11:05 (EST) 08:05 (PST) |
|
User stories for IT to support cell and gene therapies David Wallace, Facilitator, BioPhorumDoan Chau, Global Industry Technical Consultant, Rockwell Automation Sean Buckley, Chief Information Officer, Immunocore Fred Dardy, IT Portfolio Architect - Architecture & Emerging Technologies Chapter – PTIX, Roche Christian Hoferer, Team Head MES & Serialization, Roche Kim Wilson, Life Sciences Business Consultant, Dassault Systèmes |
|
Developing methods for biosimilarty studies of therapeutic monoclonal antibodies Dr. Kalhari Silva, Head of Scientific Innovation and Research, Custom Biologics |
| 16:50 17:50 (CET) 11:50 (EST) 08:50 (PST) |
|
A mid-down strategy for the mass spectrometric sequencing of progressively larger nucleic acids Dr. Dan Fabris, Harold S. Schwenk Sr. Distinguished Chair in Chemistry, University of Connecticut |
| 17:05 18:05 (CET) 12:05 (EST) 09:05 (PST) |
|
Release specifications for plasmids and master cell banks used in gene therapy Dr. Basak Clements, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson |
| 17:35 18:35 (CET) 12:35 (EST) 09:35 (PST) |
|
Ligand binding assay validation requirements and strategies Mark Dysinger, Associate Director, Alexion Pharmaceuticals |
| 17:50 18:50 (CET) 12:50 (EST) 09:50 (PST) |
|
Cell and gene therapy validation challenges Dr. Sharif Ahmed, Director, Process Validation - Global MSAT-Biotech, Bayer |
| 18:35 19:35 (CET) 13:35 (EST) 10:35 (PST) |
|
Poster session |
Sponsors
Register for free to reserve a place today — you’ll be able to drop in and out as you wish during the Summit.
Watch this space for further updates and follow our social media channels:
Spread the word using #BiopharmaSummit
Catch up on the latest techniques and technologies and play your part in improving science communication by leaving a lab product review.
_(1).gif)
.gif)
Related Articles
- Optimize drug development with advanced bioanalysis
- Bioanalytic breakthroughs redefine drug development
- Evolution in gene therapy vector analysis
- Multiplex immunofluorescence drives translational research
- ELRIG UK and SRG announce partnership to advance life science professionals
- Patient-derived organoids open doors to personalized medicine